The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment
Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
BMC
2025-01-01
|
| Collection: | BMC Complementary Medicine and Therapies |
| Sujets: | |
| Accès en ligne: | https://doi.org/10.1186/s12906-025-04753-w |